Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
33% from low
Exchange
OTC Link
CS
Borrow rate
2.23%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $26.0M | $22.3M | $0 | $0 | $9.8M | $0 |
| Cost of revenue | $0 | $297.0K | $0 | $0 | $1.8M | $1.9M | $1.4M | $1.4M |
| Gross profit | $0 | −$297.0K | $26.0M | $22.3M | −$1.8M | −$1.9M | $8.3M | −$1.4M |
| Gross margin | — | — | 100.0% | 100.0% | — | — | 85.3% | — |
| R&D | $23.7M | $27.7M | $43.1M | $66.2M | $76.3M | $71.0M | $103.4M | $28.5M |
| Operating income | −$32.8M | −$38.3M | −$29.7M | −$57.3M | −$92.9M | −$91.4M | −$114.3M | −$42.1M |
| EBITDA | −$32.2M | −$37.7M | −$29.7M | −$57.3M | −$88.0M | −$88.3M | −$113.7M | −$38.3M |
| Net income | −$32.6M | −$38.0M | −$27.8M | −$51.5M | −$86.3M | −$88.5M | −$115.1M | −$18.9M |
| Net margin | — | — | -107.2% | -231.3% | — | — | -1180.4% | — |
| EPS (diluted) | -36.18 | -39.01 | -16.89 | -28.12 | -36.50 | -26.20 | -31.16 | -7.94 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $127M | $-0.77 | $-0.77–$-0.77 | 1 |
Forward consensus · source: Financial Modeling Prep
CALITHERA BIOSCIENCES INC
No one on the platform currently holds CALA.
No tracked institution reports a position in CALA as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-06-15 | 1-for-20reverse |
No one on the platform has traded CALA yet.
| $4494 |
| — |
| KLDOKaleido Biosciences, Inc. | $0.00 | +0.00% | $4262 | — |
| ONPHOncology Pharma Inc. | $0.06 | +13.21% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Fundamental analysis of $CALA (Calithera Biosciences, Inc.) based on financial data and reported results. #CALA
View on StockTwits ↗$KALA $CALA Down 90% since post. Seems it's trying to convert to fertilizer now.
View on StockTwits ↗@Hodl707 you are right. Definitely different situation-- otherwise I would sell long time ago. $Cala has a failed asset that no one wants and the only chance for its creditors to recover anything is to find someone naive enough to provide extra funding (restructuring). This is likely the reason why this shell (cala) remains an undead zombie. BUT while we are in a much better place, there's still non-zero chance the proceeding could drag on for years.
View on StockTwits ↗Oh, and with the only asset failed in phase 2 and went BK for 2 years, $CALA still manages to beat us on share price (10x) and MC (3x). What a joke.
View on StockTwits ↗$AFMD I happened to run across $CALA and shockingly found the tick is still active and trading on Expert market. They have been in chapter 11 for over 2 years now. Will we be stucked in the same fate and will be looking at this petty 1.5k MC for next 2, 3 ,4 ,5 years?? The worst nightmare is the one that you simply cant wake up from.
View on StockTwits ↗$HUMA $HUMA Extremely bullish on $HUMA — their SYMVESS™ platform is a game-changer in synthetic biology, and with that recent DoD contract win, things are heating up fast. Upcoming earnings could be the next major catalyst, especially with a strong pipeline in the works. This one's flying under the radar but not for long. Let’s see how this plays out! $TELA $SMX $VAXX $CALA
View on StockTwits ↗$CALA so what exactly is this stock? I can only sell my shares can’t buy yet it is up 900% today I thought it was out of business
View on StockTwits ↗Tough break for $CALA. Dissolution plan signals end of road. Pipeline couldn't generate enough momentum. Biotech is brutal - one failed trial can sink a company. Watching how they monetize remaining assets. Potential value for shareholders if clinical programs get sold. straightforward update on company performance: https://beyondspx.com/article/calithera-biosciences-inc-cala-navigating-a-challenging-landscape-with-resilience
View on StockTwits ↗$AFMD two of my previously traded stocks went under due to bad data. $CALA and $ARAV both liquidated (one in process) and even when they were confirmed doomed, their stocks traded at much higher price than $AFMD (R/s adjusted). This tick has priced in a chapter 9 and liquidation with little to nothing valuable other than cash. I dont think this valuation makes any sense.
View on StockTwits ↗$CALA Calithera Biosciences (CALA): Aiming to Redefine Precision Oncology Through Targeted Small Molecules https://beyondspx.com/article/calithera-biosciences-cala-aiming-to-redefine-precision-oncology-through-targeted-small-molecules
View on StockTwits ↗$CALA Battle of the Bears Contest & Test Drive! Compete against other traders in a short only contest. Prove your trading skills Only $7.77! Via:- 𝗮𝗶𝗮𝗹𝗲𝗿𝘁.𝘂𝘀
View on StockTwits ↗$CALA Calithera Biosciences, Inc. (CALA): Navigating the Challenges of Precision Oncology http://beyondspx.com/2024/08/01/calithera-biosciences-inc-cala-navigating-the-challenges-of-precision-oncology/
View on StockTwits ↗#GoldenCross $CALA at 2.24 R11100 HiLo 7% T1Y 14 strong_buy fwdPE -2.4 DIV N/A #Calithera #stocks #trading #finance #market
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.